Assessment & Drug Effects
It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release
Drug: May potentiate hypoprothrombinemic effects of oral anticoagulants; lovastatin increases risk of myopathy and rhabdomyolysis; may increase repaglinide levels and duration of action
Assessment & Drug Effects
Use Caution/Monitor
Jun 12, 2023 tell your doctor if you have or have ever had liver or kidney disease or if you have been told you have type I diabetes mellitus
It has been associated with development of lactic acidosis and GI distress
Repaglinide is not approved for use by anyone younger than 18 years old
5 mg/day and nateglinide 180 mg/day as monotherapy, in a 16-week study, the reduction in HbA 1c values from baseline was
Last updated on Jun 29